High-dose biotin in multiple sclerosis: the end of the road

Affiliations

¹ Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum 44791, Germany.
² Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum 44791, Germany. Electronic address: ralf.gold@rub.de.

Comment

Jeremias Motte et al. Lancet Neurol. 2020 Dec.

. 2020 Dec;19(12):965-966.

doi: 10.1016/S1474-4422(20)30353-7. Epub 2020 Oct 23.

¹ Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum 44791, Germany.
² Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum 44791, Germany. Electronic address: ralf.gold@rub.de.

No abstract available

Comment on

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.